Abstract
Background: Intracerebral hemorrhage (ICH) is the most lethal subtype of stroke, a leading cause of death and disability in developed countries. Therapeutic options are notably limited. There is no specific pharmacological treatment, and early surgery has few indications that represent only a small clinically relevant survival advantage. It is therefore mandatory to investigate repairing processes after ICH in order to develop related therapeutic strategies.
Methods: The goal of this review is to discuss the current status of knowledge about the potential therapeutic role of endothelial progenitor cells (EPCs) in ICH, as well as the possible molecular mechanisms and future perspectives. Results: ICH is characterized by a primary vascular rupture, followed by a secondary vascular tearing due to the peripheral pressure exerted by the hematoma. Hypoperfusion may also play a role, although not as markedly as in ischemic stroke. In this context, the repairing of damaged vessels and the development of new ones seem logical therapeutic targets. Circulating EPCs have been suggested to play a major role in re-endothelization, angiogenesis and vasculogenesis. Congruently, EPC levels have been associated with good neurological and functional outcome as well as with reduced residual volume in patients with acute ICH. Conclusion: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH.Keywords: Angiogenesis, cellular therapy, endothelial progenitor cells, intracerebral hemorrhage, outcome, vasculogenesis.
Current Pharmaceutical Design
Title:Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Volume: 23 Issue: 15
Author(s): Juan Pías-Peleteiro, Francisco Campos, María Perez-Mato, Esteban Lopez-Arias, Manuel Rodriguez-Yanez, Jose Castillo*Tomas Sobrino*
Affiliation:
- Clinical Neurosciences Research Laboratory, Department of Neurology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela,Spain
- Department of Neurology, Clinical Neurosciences Research Laboratory, Hospital Clínico Universitário, Travesa da Choupana S/N, 15706 - Santiago de Compostela,Spain
Keywords: Angiogenesis, cellular therapy, endothelial progenitor cells, intracerebral hemorrhage, outcome, vasculogenesis.
Abstract: Background: Intracerebral hemorrhage (ICH) is the most lethal subtype of stroke, a leading cause of death and disability in developed countries. Therapeutic options are notably limited. There is no specific pharmacological treatment, and early surgery has few indications that represent only a small clinically relevant survival advantage. It is therefore mandatory to investigate repairing processes after ICH in order to develop related therapeutic strategies.
Methods: The goal of this review is to discuss the current status of knowledge about the potential therapeutic role of endothelial progenitor cells (EPCs) in ICH, as well as the possible molecular mechanisms and future perspectives. Results: ICH is characterized by a primary vascular rupture, followed by a secondary vascular tearing due to the peripheral pressure exerted by the hematoma. Hypoperfusion may also play a role, although not as markedly as in ischemic stroke. In this context, the repairing of damaged vessels and the development of new ones seem logical therapeutic targets. Circulating EPCs have been suggested to play a major role in re-endothelization, angiogenesis and vasculogenesis. Congruently, EPC levels have been associated with good neurological and functional outcome as well as with reduced residual volume in patients with acute ICH. Conclusion: An EPC-based therapy, acting primarily through angiogenic mechanisms, may be a valid therapeutic option in ICH.Export Options
About this article
Cite this article as:
Pías-Peleteiro Juan, Campos Francisco, Perez-Mato María, Lopez-Arias Esteban, Rodriguez-Yanez Manuel, Castillo Jose*, Sobrino Tomas*, Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage, Current Pharmaceutical Design 2017; 23 (15) . https://dx.doi.org/10.2174/1381612822666161221153937
DOI https://dx.doi.org/10.2174/1381612822666161221153937 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Regulation of the Cardiac Sodium/Bicarbonate Cotransporter by Angiotensin II: Potential Contribution to Structural, Ionic and Electrophysiological Myocardial Remodelling
Current Cardiology Reviews Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States
Current Diabetes Reviews Endoplasmic Reticulum Stress, Diabetes Mellitus, and Tissue Injury
Current Protein & Peptide Science Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Cardioprotection by Regular Ethanol Consumption: Potential Mechanisms and Clinical Application
Current Drug Abuse Reviews Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology The Roles of β-Carotene in Cardiomyocytes
Current Nutrition & Food Science Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Your Father and Grandfather’s Atrial Fibrillation: A Review of the Genetics of the Most Common Pathologic Cardiac Dysrhythmia
Current Genomics ErbB Targeted Drugs and Angiogenesis
Current Vascular Pharmacology Molecular Interplay between Platelets and the Vascular Wall in Thrombosis and Hemostasis
Current Vascular Pharmacology Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research Vasculogenesis and Angiogenesis Depend on the Developmental Origin in the Arterial Tree
Current Medicinal Chemistry Stem Cells Therapies in Basic Science and Translational Medicine: Current Status and Treatment Monitoring Strategies
Current Pharmaceutical Biotechnology Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy